Deerfield Management Company, L.P. (Series C) Tg Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 11,478 shares of TGTX stock, worth $346,406. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,478Holding current value
$346,406% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding TGTX
# of Institutions
336Shares Held
87.6MCall Options Held
2.35MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA15.4MShares$464 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$344 Million0.0% of portfolio
-
State Street Corp Boston, MA9.09MShares$274 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.58MShares$108 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA3.21MShares$96.7 Million0.01% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.38B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...